SOAR Trial, A Two-part Study: Interventional Phase II Single-arm Trial to Assess Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia, and an Extension With up to 60-months Follow-up
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2018
At a glance
- Drugs Ciclosporin (Primary) ; Eltrombopag (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Acronyms SOAR
- Sponsors Novartis Pharmaceuticals
- 10 May 2018 Planned End Date changed from 4 Sep 2023 to 12 Jan 2024.
- 10 May 2018 Planned primary completion date changed from 4 Sep 2023 to 12 Jul 2019.
- 06 Dec 2017 Planned End Date changed from 19 Aug 2023 to 4 Sep 2023.